🟠 Moderate Evidence
Egg quality deteriorates sharply with maternal age, a phenomenon long recognised in reproductive medicine. But new research has identified the specific cellular mechanism driving this decline—and, critically, a dietary intervention that may reverse it in animal models. According to a study published in Aging Cell (2015) by Ben-Meir and colleagues, the culprit is the age-related loss of two enzymes responsible for manufacturing coenzyme Q10 (CoQ10) inside egg cells, leading to mitochondrial dysfunction, energy depletion, and chromosome segregation errors.
Key takeaways
- Aged oocytes show significantly reduced expression of Pdss2 and Coq6, enzymes that synthesise endogenous coenzyme Q10
- This enzymatic downregulation causes mitochondrial energy failure, leading to meiotic spindle errors and aneuploidy
- Dietary CoQ10 supplementation reversed mitochondrial dysfunction in aged mice and prevented it in genetically deficient models
- The mechanism is causal—not merely correlative—as demonstrated by targeted genetic deletion studies
CoQ10 and mitochondrial function in ageing oocytes
Enzymatic capacity and ATP production decline with age; dietary supplementation restores function in animal models
Source: Ben-Meir et al., Aging Cell, 2015 | Georgian Medical Journal News
Why mitochondrial function matters in egg ageing
Human egg cells are metabolically extraordinary. Each mature oocyte contains approximately 100,000 mitochondria—far more than any other cell type—because they must power the enormous energy demands of meiotic resumption, spindle assembly, and fertilisation. According to the Ben-Meir study published in Aging Cell, those mitochondria depend critically on coenzyme Q10, a molecule that shuttles electrons between complexes I and III of the electron transport chain. When CoQ10 levels fall, the chain stalls, ATP production collapses, and meiotic machinery falters.
The research team examined oocytes from aged female mice and from older human in vitro fertilisation (IVF) patients. They found that expression of Pdss2 and Coq6—the two enzymes responsible for endogenous CoQ10 synthesis—was significantly downregulated in aged oocytes of both species. This was not a transient response to stress; it was a systematic loss of biosynthetic capacity that correlated with reduced ATP levels, meiotic spindle errors, and increased chromosomal abnormalities.
The causal mechanism: genetic proof in animal models
To establish causality rather than mere correlation, the researchers deleted the Pdss2 gene specifically in mouse oocytes. This targeted genetic deletion recapitulated the entire ageing phenotype—reduced ATP, spindle defects, and premature ovarian failure—in young animals, proving that CoQ10 insufficiency is not merely associated with age-related decline but is directly responsible for it. Similar mechanistic approaches have become standard in translational reproductive biology research, allowing researchers to move beyond epidemiological association to biological proof.
Critically, when the research team administered dietary CoQ10 to aged mice, it reversed the phenotype: ATP production recovered, meiotic spindle assembly improved, and oocyte viability was restored. In the Pdss2-deficient young mice, pre-treatment with CoQ10 prevented the phenotype entirely. The biochemical signature of CoQ10 depletion was directly confirmed in the oocytes, making the mechanism not merely hypothetical but biochemically demonstrable.
Translating animal findings to human reproductive medicine
The human implications are substantial but require careful interpretation. CoQ10 supplementation has been studied in human IVF populations, with doses ranging from 30 mg to 400 mg daily reported in clinical observational studies. However, evidence from randomised controlled trials remains limited. The Ben-Meir study’s demonstration that the biochemical lesion is reversible in aged oocytes—and preventable in genetically susceptible ones—suggests that dietary intervention targeting this specific pathway warrants further investigation in human trials.
Oocytes harvested from older IVF patients showed the same enzymatic downregulation seen in aged mice, indicating that the mechanism is conserved across species. This conservation strengthens the biological plausibility of translating the animal findings. However, human trials must account for pharmacokinetics, tissue penetration, and the practical challenge of reaching oocytes within the ovary at sufficient concentrations.
Dietary CoQ10 administration reversed mitochondrial dysfunction and aneuploidy markers in aged mouse oocytes and prevented dysfunction in Pdss2-deficient mice, establishing coenzyme Q10 insufficiency as a causal mechanism of age-related egg decline.
— Ben-Meir et al., Aging Cell (2015)
What this means
Frequently asked questions
Is CoQ10 supplementation proven to improve fertility in humans?
Not yet at the level of rigorous randomised controlled trial evidence. The Ben-Meir study was conducted in mice and human oocytes in vitro. Observational studies in human IVF patients suggest potential benefit, but larger randomised trials are needed to establish efficacy, optimal dosing, and long-term safety in reproductive populations.
At what age does CoQ10 decline in human eggs?
The Ben-Meir study did not specify an exact threshold, but documented progressive downregulation of Pdss2 and Coq6 in oocytes from older IVF patients compared to younger cohorts. Mitochondrial dysfunction and aneuploidy rates rise most steeply after maternal age 35–40, suggesting that CoQ10 decline is most pronounced in this window.
Can younger women benefit from CoQ10 supplementation?
In animal models, CoQ10 pre-treatment in genetically deficient young mice prevented mitochondrial dysfunction entirely, suggesting preventive potential. However, there is no evidence that healthy, younger women without compromised ovarian reserve require supplementation. CoQ10 may be most relevant for women of advanced maternal age or those with diminished ovarian reserve.
The Ben-Meir findings represent a shift from purely descriptive age-related decline toward mechanistically targetable biology. As reproductive medicine moves toward personalised intervention, identifying specific, reversible metabolic lesions—and dietary pathways that address them—offers a more rational foundation for clinical intervention than broad ageing narratives. Further human trials will determine whether this promise translates to clinical benefit, but the biochemical mechanism is now clear.
Source: Ben-Meir et al., Aging Cell (2015); original Facebook-shared summary from news.gmj.ge research digest
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
